Disease Classification & Relationships

Disease Classification and Relationships in Neurodegeneration

Pathway Diagram

```mermaid
flowchart TD
Disease["Neurodegeneration<br/>Disease"]

Ageing["Ageing Process"]
Frailty["Frailty<br/>Phenotype"]
RedoxSignaling["Redox Signaling<br/>Imbalance"]

MTOR["mTOR Pathway<br/>Regulation"]
MTORC1["mTORC1<br/>Complex"]
Autophagy["Autophagy<br/>Clearance"]
ATG["ATG Genes<br/>Machinery"]

CellDeath["Excessive<br/>Cell Death"]
Ferroptosis["Ferroptosis<br/>Iron Death"]
m6A["m6A RNA<br/>Modification"]

RAB7A["RAB7A<br/>Vesicle Transport"]
LAMP1["LAMP1<br/>Lysosome"]
CTSD["CTSD<br/>Protease"]

PPARG["PPARG<br/>Metabolism"]
EGFR["EGFR<br/>Growth Signal"]

Ageing -->|"increases risk"| Disease
Frailty -->|"risk factor"| Disease
RedoxSignaling -->|"associated with"| Disease
m6A -->|"dysregulates"| Disease

MTOR -->|"regulates"| MTORC1
MTORC1 -->|"inhibits"| Autophagy
Autophagy -->|"protects against"| Disease
ATG -->|"enables"| Autophagy

CellDeath -->|"contributes to"| Disease
Ferroptosis -->|"promotes"| CellDeath
RedoxSignaling -->|"triggers"| Ferroptosis

RAB7A -->|"facilitates"| Autophagy
LAMP1 -->|"required for"| Autophagy
CTSD -->|"degrades in"| LAMP1

PPARG -->|"metabolic control"| Disease
EGFR -->|"growth signaling"| MTOR

style Disease fill:#006494
style Autophagy fill:#1b5e20
style ATG fill:#1b5e20
style CellDeath fill:#ef5350
style Ferroptosis fill:#ef5350
style RedoxSignaling fi

Disease Classification and Relationships in Neurodegeneration

Pathway Diagram

Overview

Neurodegenerative diseases represent a heterogeneous group of disorders characterized by progressive loss of neuronal structure and function. Classification of these diseases is complex due to overlapping clinical presentations, mixed pathologies, and shared molecular mechanisms. This page provides a comprehensive taxonomy of neurodegenerative diseases based on protein pathology, genetic cause, clinical syndrome, and regional vulnerability[@dugger2017].

Understanding disease classification is critical for:

• Accurate diagnosis and differential diagnosis[@rascovsky2011]
• Development of disease-specific therapeutics[@scheltens2021]
• Patient stratification for clinical trials[@cummings2023]
• Understanding shared mechanisms and therapeutic targets[@jellinger2022]

Classification by Protein Pathology

The predominant aggregating protein defines major disease categories, reflecting distinct molecular pathogenesis[@kovacs2022]:

Tauopathies

| Disease | Primary Protein | Secondary Proteins | Key Brain Regions |
|---------|---------------|-------------------|------------------|
| Alzheimer's Disease (AD) | Hyperphosphorylated tau | Aβ, α-syn | Hippocampus, cortex, entorhinal cortex |
| Progressive Supranuclear Palsy (PSP) | 4R tau | None | Brainstem, basal ganglia, cortex |
| Corticobasal Degeneration (CBD) | 4R tau | TDP-43 | Motor cortex, basal ganglia |
| Primary Age-Related Tauopathy (PART) | 3R/4R tau | None | Amygdala, hippocampus |
| Argyrophilic Grain Disease (AGD) | 4R tau | None | Limbic regions |
| Chronic Traumatic Encephalopathy (CTE) | 3R/4R tau | TDP-43 | Brainstem, cortex |
| Post-Encephalitic Parkinsonism | Hyperphosphorylated tau | None | Basal ganglia, brainstem |

α-Synucleinopathies

| Disease | Primary Protein | Pathological Form | Key Brain Regions |
|---------|---------------|-------------------|------------------|
| Parkinson's Disease (PD) | α-Synuclein | LB, LN | Substantia nigra, cortex |
| Dementia with Lewy Bodies (DLB) | α-Synuclein | LB | Cortex, brainstem |
| Multiple System Atrophy (MSA) | α-Synuclein | GCI | Olives, putamen, cerebellum |
| Pure Autonomic Failure (PAF) | α-Synuclein | None | Autonomic ganglia |
| REM Sleep Behavior Disorder (RBD) | α-Synuclein | None | Brainstem |
| Parkinsonism-Dementia Complex of Guam | α-Synuclein | Tau | Brainstem, cortex |

TDP-43 Proteinopathies

| Disease | Primary Protein | Subtypes | Key Brain Regions |
|---------|---------------|----------|------------------|
| Amyotrophic Lateral Sclerosis (ALS) | TDP-43 | Classical, bulbar | Motor cortex, spinal cord |
| Frontotemporal Dementia (FTD-TDP) | TDP-43 | Type A, B, C | Frontal/temporal cortex |
| ALS/FTD | TDP-43 | Overlapping | Motor and frontal regions |
| FTLD-MND | TDP-43 | With motor neuron disease | Combined regions |

FUSopathies

| Disease | Primary Protein | Key Brain Regions |
|---------|---------------|------------------|
| ALS-FUS | FUS | Motor cortex, spinal cord |
| FTLD-FUS | FUS | Frontal/temporal cortex |
| Essential Tremor (ET) | FUS (in some) | Cerebellum |

Huntington's Disease and PolyQ Disorders

| Disease | Mutation | Protein | Key Brain Regions |
|---------|----------|---------|------------------|
| Huntington's Disease (HD) | HTT CAG expansion | Mutant huntingtin | Striatum, cortex |
| Spinocerebellar Ataxia (SCA) | Various CAG expansions | Ataxin-1, 2, 3, 7 | Cerebellum, brainstem |
| Kennedy's Disease (SBMA) | AR CAG expansion | Androgen receptor | Spinal cord |

Prion Diseases

| Disease | Prion Protein | Etiology | Key Brain Regions |
|---------|--------------|----------|------------------|
| Creutzfeldt-Jakob Disease (CJD) | PrP^Sc | Sporadic, genetic, iatrogenic | Cortex, cerebellum, basal ganglia |
| Variant CJD | PrP^Sc | Dietary BSE exposure | Lymphoid tissue, CNS |
| Fatal Familial Insomnia (FFI) | PrP^Sc | Genetic (D178N) | Thalamus |
| Gerstmann-Sträussler-Scheinker (GSS) | PrP^Sc | Genetic | Cerebellum |

Mixed Proteinopathies

| Disease | Primary Protein | Co-pathology | Prevalence |
|---------|---------------|--------------|------------|
| AD/LB | Tau, α-syn | Lewy bodies | 30-50% of AD |
| AD/TDP | Tau, TDP-43 | TDP-43 inclusions | 20-30% of AD |
| DLB/AD | α-syn, Tau | amyloid plaques | 60-80% of DLB |
| PSP/CBS | Tau | Variable | 20% overlap |
| ALS/FTD | TDP-43 | Variable | 15% of ALS |

Classification by Genetic Cause

Autosomal Dominant Neurodegeneration

| Gene | Protein | Disease | Mechanism |
|------|---------|---------|-----------|
| [APP](/genes/app) | Amyloid precursor protein | AD, CAA | Aβ overproduction |
| [PSEN1](/genes/psen1) | Presenilin-1 | AD | Aβ overproduction |
| [PSEN2](/genes/psen2) | Presenilin-2 | AD | Aβ overproduction |
| [SNCA](/genes/snca) | α-Synuclein | PD, DLB | Gain of function, aggregation |
| [LRRK2](/genes/lrrk2) | Leucine-rich repeat kinase 2 | PD | Kinase hyperactivity |
| [MAPT](/genes/mapt) | Tau | CBD, PSP, AGD | Tau dysfunction |
| [GRN](/genes/grn) | Progranulin | FTLD-TDP | Haploinsufficiency |
| C9orf72 | C9orf72 | ALS/FTD | Hexanucleotide repeat, dipeptide toxicity |
| SOD1 | Cu/Zn superoxide dismutase | ALS | Gain of toxic function |
| FUS | FUS | ALS/FTD | RNA processing dysfunction |
| TARDBP | TDP-43 | ALS/FTD | Aggregation |
| HTT | Huntingtin | HD | Gain of toxic function |
| ATXN1 | Ataxin-1 | SCA1 | Polyglutamine toxicity |
| ATXN2 | Ataxin-2 | SCA2, ALS | RNA toxicity |

Autosomal Recessive Neurodegeneration

| Gene | Protein | Disease | Mechanism |
|------|---------|---------|-----------|
| [PARKIN](/genes/parkin) | Parkin | PD (EOMRK) | Mitophagy dysfunction |
| [PINK1](/genes/pink1) | PINK1 | PD (EOMRK) | Mitophagy dysfunction |
| [GBA](/genes/gba) | Glucocerebrosidase | PD, DLB | Lysosomal dysfunction |
| DJ-1 | DJ-1 | PD | Oxidative stress response |
| ATP13A2 | ATP13A2 | Kufor-Rakeb syndrome | Lysosomal dysfunction |
| WDR45 | WDR45 | BPAN | Autophagy dysfunction |
| Progranulin | Progranulin | FTLD-TDP (homozygous) | Loss of function |

Polygenic/Sporadic Forms

Most neurodegenerative diseases are sporadic, with risk determined by multiple genetic variants identified through GWAS[@wightman2022]:

| Disease | GWAS Loci | Heritability (h²) |
|---------|-----------|------------------|
| AD | >40 | 60-80% |
| PD | >90 | 22-27% |
| ALS | >10 | 12-21% |
| FTD | >15 | 40% |
| HD | 1 (HTT) | 100% (monogenic) |

Classification by Clinical Syndrome

Dementia Syndromes

| Syndrome | Core Features | Pathological Correlates |
|----------|--------------|------------------------|
| Alzheimer's Disease | Memory loss, cognitive decline | Aβ plaques, NFT |
| Frontotemporal Dementia | Behavioral change, language deficits | Tau, TDP-43 |
| Dementia with Lewy Bodies | Fluctuating cognition, visual hallucinations, parkinsonism | Lewy bodies |
| Vascular Dementia | Stepwise decline, focal signs | Vascular lesions |
| Posterior Cortical Atrophy | Visual deficits, agraphia | Posterior tau/Aβ |
| Primary Progressive Aphasia | Language impairment | Frontotemporal pathology |

Movement Disorders

| Disorder | Core Features | Pathological Correlates |
|----------|--------------|------------------------|
| Parkinson's Disease | Resting tremor, bradykinesia, rigidity | Lewy bodies |
| Progressive Supranuclear Palsy | Vertical gaze palsy, postural instability | 4R tau |
| Corticobasal Degeneration | Apraxia, alien limb, cortical sensory loss | 4R tau |
| Multiple System Atrophy | Autonomic failure, parkinsonism/cerebellar | α-syn (GCI) |
| Huntington's Disease | Chorea, behavioral change, dementia | Mutant huntingtin |
| Ataxias | Gait instability, coordination loss | Various |
| Dystonia | Involuntary movements, abnormal postures | Various |

Motor Neuron Diseases

| Disorder | Core Features | Pathological Correlates |
|----------|--------------|------------------------|
| Amyotrophic Lateral Sclerosis | Progressive weakness, fasciculations | TDP-43 |
| Progressive Lateral Sclerosis (PLS) | Upper motor neuron signs | TDP-43 (some) |
| Progressive Muscular Atrophy (PMA) | Lower motor neuron signs | TDP-43 (some) |
| Kennedy's Disease | Adult-onset, slow progression | Androgen receptor |

Regional Vulnerability Patterns

Brainstem Predominant

| Disease | Vulnerable Nuclei | Neurotransmitter |
|---------|------------------|------------------|
| Parkinson's Disease | Substantia nigra (SNpc), VTA | Dopamine |
| Progressive Supranuclear Palsy | Superior colliculus, PAG | Multiple |
| Multiple System Atrophy | Dorsal motor nucleus, inferior olive | Multiple |
| REM Sleep Behavior Disorder | Sublaterodorsal nucleus | GABA/glycine |

Basal Ganglia Predominant

| Disease | Vulnerable Structures | Neurotransmitter |
|---------|---------------------|------------------|
| Huntington's Disease | Striatum (MSNs) | GABA |
| Multiple System Atrophy | Putamen, globus pallidus | Multiple |
| Parkinson's Disease | Substantia nigra pars compacta | Dopamine |
| Corticobasal Degeneration | Striatum, GP | Multiple |

Cortical Predominant

| Disease | Vulnerable Regions | Pathological Proteins |
|---------|-------------------|----------------------|
| Alzheimer's Disease | Hippocampus, entorhinal, cortex | Aβ, Tau |
| Frontotemporal Dementia | Frontal, temporal cortex | Tau, TDP-43 |
| Dementia with Lewy Bodies | Cortex, limbic system | α-Syn |
| Corticobasal Degeneration | Motor, premotor cortex | Tau |

Cerebellar Predominant

| Disease | Vulnerable Cells | Pathology |
|---------|-----------------|-----------|
| Multiple System Atrophy | Purkinje cells, olive | α-Syn |
| Spinocerebellar Ataxias | Purkinje cells, granule cells | Various |
| Paraneoplastic Cerebellar Degeneration | Purkinje cells | Anti-Yo, anti-Hu |

Cell Type Vulnerability Rankings

NeuroWiki contains 3,545 cell type pages covering the full spectrum of neuronal and glial cell types in the nervous system. These include 1,745 neuron subtypes and 158 glial cell types[@zeisel2018].

Tier 1: Highly Vulnerable

| Rank | Cell Type | Disease Association | Evidence Level |
|------|-----------|---------------------|----------------|
| 1 | [Dopaminergic Neurons (SNpc)](/cell-types/dopaminergic-neurons-snpc) | [Parkinson's Disease](/diseases/parkinsons-disease) | Strong[@survival2019] |
| 2 | [Motor Neurons](/cell-types/motor-neurons) | ALS | Strong[@motor2020] |
| 3 | [Hippocampal CA1 Pyramidal Neurons](/cell-types/hippocampal-ca1-neurons) | [Alzheimer's Disease](/diseases/alzheimers-disease) | Strong[@hippocampal2018] |
| 4 | [Cholinergic Neurons (Basal Forebrain)](/cell-types/cholinergic-neurons) | Alzheimer's Disease | Strong[@cholinergic2017] |
| 5 | [Noradrenergic Neurons (Locus Coeruleus)](/cell-types/noradrenergic-neurons-locus-coeruleus) | AD, PD | Strong[@noradrenergic2019] |

Tier 2: Moderately Vulnerable

| Rank | Cell Type | Disease Association | Evidence Level |
|------|-----------|---------------------|----------------|
| 6 | [Serotonergic Neurons (Raphe Nuclei)](/cell-types/serotonergic-neurons-raphe) | PD, Depression | Moderate[@serotonergic2021] |
| 7 | [Medium Spiny Neurons (MSNs)](/cell-types/medium-spiny-neurons) | Huntington's Disease | Strong[@striatal2021] |
| 8 | [Purkinje Cells](/cell-types/purkinje-cells) | Ataxias, SCA | Strong[@purkinje2020] |
| 9 | [Olfactory Bulb Mitral Cells](/cell-types/mitral-cells) | PD (Early) | Moderate[@olfactory2019] |
| 10 | [Cortical Pyramidal Neurons](/cell-types/pyramidal-neurons) | FTD, AD | Moderate[@cortical2020] |

Vulnerability Mechanisms

Cell-Intrinsic Factors:

• High metabolic demand: Energy-intensive processes make [neurons](/entities/neurons) susceptible to mitochondrial dysfunction[@mitochondrial2020]
• Large axonal projections: Increased vulnerability to transport deficits
• Calcium dysregulation: Excitotoxicity and calcium overload[@calcium2019]
• Protein aggregation susceptibility: Selective vulnerability to misfolded proteins[@protein2018]

• [Microglia](/cell-types/microglia-neuroinflammation): Chronic neuroinflammation drives neurodegeneration[@microglia2019]
• [Astrocytes](/entities/astrocytes): Loss of supportive functions and glutamate uptake
• Oligodendrocytes: Myelin degeneration in MSA and AD[@oligodendrocyte2020]

Cross-Linking to Key Genes

• [APP](/genes/app)
• [PSEN1](/genes/psen1)
• [SNCA](/genes/snca)
• [LRRK2](/genes/lrrk2)
• [PARKIN](/genes/parkin)
• [PINK1](/genes/pink1)
• [GBA](/genes/gba)
• [MAPT](/genes/mapt)
• [GRN](/genes/grn)
• [C9orf72](/genes/c9orf72)
• [SOD1](/genes/sod1)
• [FUS](/genes/fus)
• [TARDBP](/genes/tardbp)
• [HTT](/genes/htt)

See Also

• [Cell Types Directory](/cell-types)
• [Cell Atlas Coverage](/cell-types/cell-atlas-coverage)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
• [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
• [Huntington's Disease](/diseases/huntingtons)
• [Multiple System Atrophy](/diseases/multiple-system-atrophy)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
• [Alzheimer's Disease Genetics Consortium](https://adgenetics.org/)
• [International Parkinson Disease Genomics Consortium](https://pdgenetics.org/)

References